Search Within

Advanced Practice Providers

  1. "Matthew Matasar"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (11)
Groups
  1. Center for Hematologic Malignancies (37)
  2. Department of Medicine (37)
  3. Hematologic Malignancies, Division of (37)
  4. Lymphoma (37)
  5. Survivorship Research (37)
  6. Nursing (28)

More Groups

People
  1. Matthew Matasar (37)
  2. Andrew Zelenetz (32)
  3. Alison Moskowitz (27)
  4. Ariela Noy (26)
  5. Maria Palomba (26)
  6. Paul Hamlin (25)

More People

Years
  1. 2022 (3)
  2. 2021 (7)
  3. 2020 (2)
  4. 2019 (4)
  5. 2018 (3)
  6. 2017 (4)

More Years

Publications
  1. Blood (19)
  2. Journal of Clinical Oncology (5)
  3. Hematological Oncology (3)
  4. Annals of Oncology (2)
  5. American Journal of Hematology (1)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. American Society of Clinical Oncology (5)
  3. Wiley Blackwell (3)
  4. Elsevier Inc. (2)
  5. Elsevier Science, Inc. (2)
  6. Oxford University Press (2)

More Publishers

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin combined with AVD chemotherapy and radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L. E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S.; Drill, E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of pre-transplant rituximab on efficacy of revaccination of lymphoma patients after autologous hematopoietic stem cell transplantation
    Meeting Abstract

    Preston, E. V.; Palazzo, M. A.; Seier, K.; Devlin, S. M.; Giralt, S.; Scordo, M.; Dahi, P. B.; Matasar, M. J.; Moskowitz, C. H.; Sauter, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save